Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Robust report on 162 patients with EGFR transformed SCLC.
Median time to transformation: 25.8m. Post transformation OS: 14.2m.
- 1L chemo PFS: 5.3m
- 1L chemo + TKI PFS: 6.2m
- 1L chemo + IO PFS: 4.1m
Later line taxane PFS: 6.9m. Later line captothecin PFS: 1.1m.”
Title: Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis
Authors: Ruolin Gao, ZhenXiang Li, Jie Huang, Jun Zhao, Yan Wang, Qinxiang Guo, Guangchuan Deng, Hua Bai, Xu Yang, Jianchun Duan, Zhijie Wang, Yuyan Wang, Jingjing Wang, Jiachen Xu, Rui Wan, Boyang Sun, Kailun Fei, Zixiao Ma, Jia Zhong, Jie Wang
Read the full article.
You might find this interesting:
TP53-Mutated EGFR NSCLC: Powerful PFS Gain With Combination Therapy
